ATTO Earnings Results and History
Attovia Therapeutics, Inc.'s earnings at a glance: the latest results and outlook from the press release, revenue, margins and EPS for every quarter from the company's SEC filings, and how the stock moved after each report. New results show here within about a minute of being filed.
- EPS−$0.76
- Revenue–
Filed ยท Press release
Key takeaways
from the press release- No collaboration revenue in Q3 2026, versus $0.4 million a year earlier from the EndPath license.
- R&D rose to $20.3 million from $12.3 million, driven by ATTO-1310 Phase 1 and IND-enabling program costs.
Filings and dates
SEC EDGAR- Feb 8, 2027Next earnings reportexpected
- Nov 9, 2026Earnings release, Q3 20268-K Press release
Also see ATTO institutional ownership and the earnings calendar.
ATTO earnings FAQ
What were ATTO's latest earnings?
For Q3 2026 Attovia Therapeutics, Inc. reported, GAAP EPS of -$0.76. The results were filed with the SEC on Nov 9, 2026.
When is ATTO's next earnings date?
Attovia Therapeutics, Inc. is expected to report on Feb 8, 2027. Dates can move until the company confirms them.
Where do these numbers come from?
Results, guidance and financials come from Attovia Therapeutics, Inc.'s own SEC filings: the earnings press release (Form 8-K) and the quarterly and annual reports (10-Q and 10-K). Key takeaways summarize the press release. Estimates and price moves come from market data.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Results come from company filings with the SEC. Estimates are consensus figures from before each report. Key takeaways summarize the company's press release and may contain errors; the press release is the authoritative source.